# EDGAR Filing Document

**Accession Number:** 0000927653
**File Stem:** 0000927653-25-000045
**Filing Date:** 2025-6
**Character Count:** 10616
**Document Hash:** 7259871822110827eb329f4d5e027a4e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000927653-25-000045.hdr.sgml**: 20250609

**ACCESSION NUMBER**: 0000927653-25-000045

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250609

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20250609

**DATE AS OF CHANGE**: 20250609

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MCKESSON CORP
- **CENTRAL INDEX KEY:** 0000927653
- **STANDARD INDUSTRIAL CLASSIFICATION:** WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 943207296
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-13252
- **FILM NUMBER:** 251032858

**BUSINESS ADDRESS:**
- **STREET 1:** 6555 STATE HIGHWAY 161
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039
- **BUSINESS PHONE:** 972-446-4800

**MAIL ADDRESS:**
- **STREET 1:** 6555 STATE HIGHWAY 161
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MCKESSON HBOC INC
- **DATE OF NAME CHANGE:** 19990115

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MCKESSON CORP
- **DATE OF NAME CHANGE:** 19950209

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SP VENTURES INC
- **DATE OF NAME CHANGE:** 19940728

?xml version='1.0' encoding='ASCII'? mck-20250609

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): June 9, 2025**![mckessonlogoa04.jpg](mck-20250609_g1.jpg)

**McKESSON CORPORATION** 

**(Exact Name of Registrant as Specified in Charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **1-13252** | **94-3207296** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission<br>File Number)** | **(I.R.S. Employer<br>Identification No.)** |

---

**6555 State Hwy 161** 

**Irving, TX 75039** 

**(Address of Principal Executive Offices, and Zip Code)**

**(972) 446-4800** 

**Registrant's Telephone Number, Including Area Code**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common stock, $0.01 par value | MCK | New York Stock Exchange |
| 1.500% Notes due 2025 | MCK25 | New York Stock Exchange |
| 1.625% Notes due 2026 | MCK26 | New York Stock Exchange |
| 3.125% Notes due 2029 | MCK29 | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.** |

---

Today, June 9, 2025, McKesson Corporation's (McKesson) executives are scheduled to meet with various investors and analysts. During these meetings, they will discuss McKesson's growth strategies, operational performance, business and market trends and financial outlook.

Today, McKesson is providing the following updates to its Fiscal Year 2026 Financial Outlook. McKesson is increasing its full year Adjusted Earnings per Diluted Share guide from a range of $36.75 to $37.55, to a new range of $36.90 to $37.70. McKesson is reaffirming its full year effective tax rate guidance of 17% to 19%. McKesson anticipates the effective tax rate for the first half of the fiscal year to be 17% to 20%, with a higher rate in Q1 than Q2, and the second half effective tax rate to be 16% to 19%. McKesson is reaffirming all other guidance provided on its earnings call on May 8, 2025.

**Non-GAAP Financial Measures**

GAAP refers to the U.S. generally accepted accounting principles. This report includes the Non-GAAP financial measure Adjusted Earnings per Diluted Share, which is not calculated in accordance with GAAP. McKesson does not provide forward-looking guidance on a GAAP basis as the company is unable to provide a quantitative reconciliation of forward-looking Non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort. McKesson cannot reasonably forecast LIFO inventory-related adjustments, certain litigation loss and gain contingencies, restructuring, impairment and related charges, and other adjustments, which are difficult to predict and estimate. These items are generally uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially. Refer to the "Supplemental Non-GAAP Financial Information" section of the financial statement tables accompanying McKesson's Form 8-K submission on May 8, 2025, for the definitions and descriptions of usefulness of McKesson's Non-GAAP financial measures.

**Cautionary Statements**

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by their use of terminology such as "anticipates," "outlook" and "guidance" and include projections about Adjusted Earnings per Diluted Share. Readers should not place undue reliance on these forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, we undertake no obligation to update or revise our forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, we encourage investors to read the risk factors described in our publicly available filings with the Securities and Exchange Commission and news releases.

These risk factors include, but are not limited to: we experience costly and disruptive legal disputes and settlements, including regarding our role in distributing controlled substances such as opioids; we experience losses not covered by insurance or indemnification; we are subject to frequently changing, extensive, complex, and challenging healthcare and other laws; we from time to time record significant charges from impairment to goodwill, intangibles, and other long-lived assets; we experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches; we experience significant problems with information systems or networks; we may be unsuccessful in achieving our strategic growth objectives; we may be unsuccessful in our efforts to implement initiatives to reduce or optimize our costs; we might be unable to successfully complete or integrate acquisitions or other strategic transactions, especially in the timeframes noted; we might be adversely impacted by delays or other difficulties with divestitures; we may not receive anticipated benefits from acquisitions or other strategic transactions; we are impacted by customer purchase reductions, contract non-renewals, payment defaults, and bankruptcies; our contracts with government entities involve future funding and compliance risks; we might be harmed by changes in our relationships or contracts with suppliers; our use of third-party data is subject to risks and limitations that could impede the growth of our data services business; we might be unable to successfully recruit and retain qualified employees; we might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models; we might be adversely impacted by competition and industry consolidation; we are adversely impacted by changes or disruptions in product supply and have difficulties in sourcing or selling products due to a variety of causes; we are adversely impacted as a result of our distribution of generic pharmaceuticals; we are adversely impacted by changes in the economic environments in which we operate; changes affecting capital and credit markets might impede access to credit, increase borrowing costs, and disrupt banking services for us and our customers and suppliers and might impair the financial soundness of our customers and suppliers; we might be adversely impacted by changes in tax legislation or challenges to our tax positions; we might be adversely impacted by conditions and events outside of our control, such as widespread public health issues, natural disasters, and geopolitical factors; we may be adversely affected by global climate change or by regulatory or market responses to such change; and evolving expectations and regulatory requirements related to governance and sustainability matters, including those concerning human capital management, climate change, environmental responsibility, and social impact may have an adverse effect on our business, financial condition, and results of operations and damage our reputation.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 9, 2025

---

| | |
|:---|:---|
| **McKesson Corporation** | **McKesson Corporation** |
| By: | /s/ Britt J. Vitalone |
|  | Britt J. Vitalone |
|  | Executive Vice President and  |
|  | Chief Financial Officer |

---